Bioventus Inc. (NYSE:BVS) Shares Purchased by Acadian Asset Management LLC

Acadian Asset Management LLC boosted its holdings in shares of Bioventus Inc. (NYSE:BVS) by 403.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,956 shares of the company’s stock after purchasing an additional 22,399 shares during the period. Acadian Asset Management LLC’s holdings in Bioventus were worth $159,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Jump Financial LLC purchased a new stake in shares of Bioventus during the 4th quarter worth about $122,000. Quadrature Capital Ltd purchased a new position in Bioventus during the fourth quarter worth approximately $85,000. GSG Advisors LLC grew its holdings in Bioventus by 55.8% in the first quarter. GSG Advisors LLC now owns 26,511 shares of the company’s stock valued at $133,000 after purchasing an additional 9,500 shares during the period. LSV Asset Management purchased a new stake in shares of Bioventus in the first quarter valued at approximately $1,170,000. Finally, SG Americas Securities LLC acquired a new position in shares of Bioventus during the 1st quarter worth approximately $66,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director John A. Bartholdson purchased 25,500 shares of the company’s stock in a transaction dated Monday, August 19th. The stock was acquired at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the transaction, the director now directly owns 6,939,357 shares of the company’s stock, valued at $59,331,502.35. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director John A. Bartholdson acquired 25,500 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was purchased at an average cost of $8.55 per share, for a total transaction of $218,025.00. Following the completion of the transaction, the director now owns 6,939,357 shares in the company, valued at $59,331,502.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John A. Bartholdson bought 80,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was purchased at an average price of $8.55 per share, for a total transaction of $684,000.00. Following the completion of the acquisition, the director now directly owns 6,913,857 shares in the company, valued at $59,113,477.35. The disclosure for this purchase can be found here. Corporate insiders own 32.90% of the company’s stock.

Bioventus Stock Up 2.2 %

Shares of BVS opened at $11.85 on Friday. The stock has a 50 day moving average price of $8.79 and a 200 day moving average price of $6.66. Bioventus Inc. has a one year low of $2.82 and a one year high of $12.03. The company has a debt-to-equity ratio of 1.82, a quick ratio of 0.96 and a current ratio of 1.33. The stock has a market capitalization of $938.12 million, a price-to-earnings ratio of -33.86 and a beta of 0.89.

Bioventus (NYSE:BVS) last released its earnings results on Tuesday, August 6th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.07 by $0.12. The business had revenue of $151.22 million during the quarter, compared to analyst estimates of $137.70 million. Bioventus had a negative net margin of 7.82% and a positive return on equity of 14.39%. During the same quarter in the prior year, the firm earned $0.14 earnings per share. Equities research analysts forecast that Bioventus Inc. will post 0.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BVS. Canaccord Genuity Group boosted their price target on shares of Bioventus from $8.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, August 13th. Craig Hallum upped their price target on shares of Bioventus from $9.00 to $12.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.